Global Patient Blood Management Market is valued at approximately USD 12.2 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.3% over the forecast period 2022-2029. Patient Blood Management is a multidisciplinary approach to caring for patients who might need a blood transfusion. The Patient Blood Management market is expanding because of factors such as rising incidence of trauma and accidents that causes blood loss and Increasing in the prevalence of blood cancer.

According to the Statista, the number of road-traffic related injuries in the United States has decreased by roughly 17 percent between 2019 and 2020, whereas fatalities increased by almost 8 percent. Between 2010 and 2020, road traffic injuries in the United States grew by nearly 34,000 incidents to some 2.28 million road traffic related injuries in 2020. Over the same period, fatalities also increased by about 5,800. Another important component driving space is Increasing in the prevalence of blood cancer. As per Statista, in 2020, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 16 million by 2040. In addition, in 2021, global oncology spending totaled 187 billion U.S. dollars. In comparison, costs stood at 86 billion dollars six years earlier. However, lack of awareness regarding blood donation stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Patient Blood Management Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific dominated the space in terms of revenue, owing to the rise in the number of hospitals and growing elderly population that is vulnerable to blood diseases. Moreover, North America is expected to grow significantly during the forecast period, owing to factors such as Increasing Government initiatives and nonprofit organizations in the market space.

Major market player included in this report are:

Grifols, S.A.
B. Braun SE
Immucor, Inc
Haemonetics Corporation
LivaNova PLC
Biomerieux SA
Haier Biomedical
Macopharma
Terumo Corporation
Asahi Kasei Corporation
Recent Developments in the Market:
? In February 2022, Biocon announced the acquisition of Viatris’ biosimilar portfolio for USD 3.335 billion. This acquisition strengthened Biocon’s biosimilar product portfolio and improved its revenue generation.
Global Patient Blood Management Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Component, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Instruments
Accessories
Reagents and Kits
Software

By Component:
Whole Blood and Red Blood Cells
Plasma

By End User:
Blood Banks
Hospitals
Diagnostic Clinics and Pathology Labs

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World